Name

Neopharm Israel

Legal name

Neopharm Ltd. & Neopharm (Israel) 1996, Ltd.

Website

https://neopharmisrael.com

Company type

Private

Founded year

1941

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution and Commercialization

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Pharmaceutical distribution
• Medical device distribution
• Pharmaceutical commercialization
• Market access services
• Regulatory affairs services

Headquarters

HQ city

Petah Tiqva

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Distribution and Commercialization: Neopharm Israel generates revenue through importing, marketing, sales, and distribution of pharmaceuticals and medical devices to the Israeli market. As a commercialization platform, they work with global healthcare companies to bring products to market in Israel, handling regulatory approval, product management, sales, and distribution.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Neopharm Israel is a pharmaceutical and medical device commercialization platform that imports, markets, sells, and distributes prescription products on behalf of global pharmaceutical and biotech companies in the Israeli market. The company delivers end-to-end services covering regulatory approval, scientific and medical engagement, marketing and launch execution, early access programs, strategic product management, a high-performance field sales force, home care services, and full supply chain distribution. It is ranked the #1 distributor of pharmaceuticals and medical devices in Israel by Dun & Bradstreet (2024).

Product overview

Neopharm Israel operates as a unified pharmaceuticals commercialization platform providing integrated, end-to-end solutions for global healthcare companies entering the Israeli market. The core offering is pharmaceutical and medical device distribution (#1 ranked by Dun & Bradstreet as of 2024), supported by eight interconnected service modules: Regulatory Excellence, Scientific and Medical Expertise, Marketing and Launch Success, Early Access Programs, Strategic Product Management, High-Performance Sales Teams, Home Care Services, and Supply Chain and Distribution. Together these services turn innovation into impact by managing the complete product lifecycle from import through marketing, sales, and final delivery to patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Integrated Pharmaceuticals Commercialization Platform End-to-end commercialization service for global pharmaceutical and biotech companies seeking to bring prescription drugs and medical devices to the Israeli market. The platform covers import, regulatory approval, scientific and medical engagement, marketing and launch execution, early access programs, strategic product management, a high-performance field sales force conducting over 50,000 physician meetings annually, home care services, and full supply chain distribution. Ranked #1 distributor of pharmaceuticals and medical devices in Israel by Dun & Bradstreet (2024). Customers are global pharma and biotech companies; downstream users are Israeli physicians and patients.

Quantifiable outcome

• Over 50 indications gained reimbursement in the last decade
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Leading Global Pharmaceutical CompaniescoreChannel Partner/ Reseller/ DistributorNeopharm Israel has established long-standing partnerships with leading global pharmaceutical and biotech companies since 1941. They serve as the trusted commercialization platform for bringing life-changing treatments to patients in Israel, providing seamless local market integration through their comprehensive end-to-end solutions.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Sanofi Israel: Israeli operation of a global pharma major covering specialty, vaccines, and consumer health. Comparable as another broad multinational incumbent distributing through both direct and partner channels in Israel.
• Teva Pharmaceutical Industries: Israel's flagship global pharmaceutical company with dominant generic and specialty pharma operations. Comparable as a broad incumbent Israel-headquartered pharma major with significant local distribution and commercialization footprint.
• Perrigo Israel (Agis Industries heritage): Global consumer healthcare and generics company with historical roots in Israel through Agis. Comparable as a broad incumbent with established distribution and brand operations in the Israeli pharma market.
• Novartis Pharma Israel: Israeli affiliate of a leading global pharma innovator with in-country sales, medical, and market access teams. Comparable as a multinational pharma incumbent that either partners with Neopharm or represents an alternative commercialization route for global launches in Israel.
• Pfizer Pharmaceuticals Israel: Israeli affiliate of a top global pharma major running direct sales, medical, and regulatory operations in Israel. Comparable as the type of multinational that Neopharm often serves as commercial partner, representing a potential partner-or-rival dynamic.

Direct peers

• Medison Pharma: Israel-founded pharma commercialization platform that partners with global biotechs to bring specialty and rare-disease therapies to multiple markets. Highly comparable business model to Neopharm, focused on market access, regulatory, and distribution rather than in-house manufacturing.
• CTS Chemical Industries: Israeli pharmaceutical and consumer healthcare company with marketing and distribution of drugstore products in Israel. Comparable as a domestic Israel pharma distribution and commercialization player serving similar healthcare channels.
• Rafa Laboratories: Long-established Israeli pharmaceutical company operating in manufacturing, marketing, and distribution of branded and generic medicines domestically. Comparable as a local Israeli player combining in-country pharma operations with distribution partnerships.
• Dexcel Pharma Israel: Israel-based specialty pharmaceutical company developing, licensing, and distributing proprietary therapies in Israel and select markets. Comparable as a domestic pharma company combining product management with Israeli market commercialization.

Others

• Neopharm Group (parent affiliate): Group entity referenced on Neopharm Israel's own website that 'unites industry-leading companies in healthcare.' Comparable as the broader affiliated corporate vehicle that shapes Neopharm Israel's strategic positioning within Israeli healthcare.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neopharm-israel_2

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neopharm Israel